Publications (58) Laura Andrea Charola Ramos publications

filter_list

2025

  1. Disease clearance in ulcerative colitis: What is it? What does it involve? How do we translate it into spanish?

    Gastroenterologia y Hepatologia

  2. Ileal Predominance in Crohn's Disease Is Associated With Increased Intestinal Surgery and Biological Therapy Use, With Lower Treatment Persistence

    The American journal of gastroenterology, Vol. 120, Núm. 1, pp. 194-203

  3. Types, behaviour and therapeutic requirements of inflammatory pouch disorders: Results from the RESERVO study of GETECCU

    Digestive and Liver Disease, Vol. 57, Núm. 2, pp. 566-573

2024

  1. Diseño de una herramienta para la clasificación de pacientes en base a su actitud farmacoterapéutica

    Farmacéuticos comunitarios, Vol. 16, Núm. 2

  2. Effectiveness and safety of azathioprine for inflammatory pouch disorders: results from the RESERVO study of GETECCU

    Therapeutic Advances in Gastroenterology, Vol. 17

  3. Evaluation of Genetic Variants Associated with the Risk of Thiopurine-Related Pancreatitis: A Case Control Study from ENEIDA Registry

    Digestive Diseases, Vol. 42, Núm. 3, pp. 257-264

  4. Long-term benefit of ustekinumab in ulcerative colitis in clinical practice: ULISES study

    Alimentary Pharmacology and Therapeutics, Vol. 60, Núm. 10, pp. 1325-1338

  5. Sex-Related Differences in the Phenotype and Course of Inflammatory Bowel Disease: SEXEII Study of ENEIDA

    Clinical Gastroenterology and Hepatology, Vol. 22, Núm. 11, pp. 2280-2290

  6. Sickle Cell Anemia Screening in Newborns and Analysis of Haplotypes in Patients from Santiago Island, Cape Verde

    Anemia, Vol. 2024

2023

  1. COVID-19 vaccination rate and willingness of an additional dose among inflammatory bowel disease patients receiving biologic therapy: Fearless and with desire

    Gastroenterologia y Hepatologia, Vol. 46, Núm. 4, pp. 255-260

  2. Disease clearance in ulcerative colitis: Setting the therapeutic goals for future in the treatment of ulcerative colitis

    Frontiers in Medicine

  3. Efficacy, Efficiency, and Acceptability of Telemedicine for Inflammatory Bowel Disease Patients' Follow-Up Care during the COVID-19 Pandemic

    Digestive Diseases, Vol. 41, Núm. 4, pp. 574-580

  4. Hematological Composite Scores in Patients with Inflammatory Bowel Disease

    Journal of Clinical Medicine, Vol. 12, Núm. 23

  5. Impact of Biologic Agents on the Immune Response Induced by the Additional Dose of SARS-CoV-2 Vaccine in Inflammatory Bowel Disease Patients

    Inflammatory bowel diseases, Vol. 29, Núm. 7, pp. 1165-1169

  6. Non-hepatic Solid Organ Transplant in Patients with Inflammatory Bowel Disease: An ECCO CONFER Multicentre Case Series

    Journal of Crohn's & colitis, Vol. 17, Núm. 7, pp. 1097-1102

  7. Real-World Evidence of Tofacinitib in Ulcerative Colitis: Short-Term and Long-Term Effectiveness and Safety

    American Journal of Gastroenterology, Vol. 118, Núm. 7, pp. 1237-1247

  8. Serum Levels of Lipoprotein Lipase Are Increased in Patients with Inflammatory Bowel Disease

    International journal of molecular sciences, Vol. 24, Núm. 6

2022

  1. Adherence to subcutaneous biologic treatment for inflammatory bowel disease

    Gastroenterologia y Hepatologia, Vol. 45, Núm. 5, pp. 335-341

  2. Apolipoprotein C3 Is Downregulated in Patients With Inflammatory Bowel Disease

    Clinical and translational gastroenterology, Vol. 13, Núm. 6, pp. e00500

  3. Immigrant IBD Patients in Spain Are Younger, Have More Extraintestinal Manifestations and Use More Biologics Than Native Patients

    Frontiers in Medicine, Vol. 9